BPA
SLN

Beacon Pointe Advisors’s Silence Therapeutics SLN Stock Holding History

Beacon Pointe Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,615
Closed -$67.4K – 1514
2025
Q2 		$67.4K Buy
+11,615
New +$49.8K ﹤0.01% 1233

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Beacon Pointe Advisors's SLN Position: Q3 2025 in Review

Beacon Pointe Advisors sold out of Silence Therapeutics (SLN) in Q3 2025, closing a stake of 11,615 shares — an estimated $67.4K sold.

Beacon Pointe Advisors first reported a position in SLN in Q2 2025 and held it in 1 quarter. The position peaked at $67.4K in Q2 2025. 54 funds tracked by Wall St. Rank hold SLN as of Q3 2025.

  • Beacon Pointe Advisors reported no remaining Silence Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Beacon Pointe Advisors sold 11,615 Silence Therapeutics shares in Q3 2025, an estimated $67.4K.
  • Beacon Pointe Advisors first reported a position in Silence Therapeutics in Q2 2025 and held it in 1 quarter.
  • Beacon Pointe Advisors's Silence Therapeutics position peaked at $67.4K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2025.

Based on Beacon Pointe Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.